Pharmaceuticals and Environment

Here you can find information about the environmental impact of human pharmaceuticals. You can search for a substance name. The environmental risk refers to the use of a pharmaceutical. The knowledge support is based on three sources:
- environmental information from the European Medicines Agency's (EMA's) European Public Assessment Reports (EPARs) with risk assessed from a European perspective
- environmental information on Fass.se and risk based on the total sales of an active substance in Sweden during a given year
- environmental risk assessments for certain substances based on concentrations measured in the environment in Sweden and effect studies.
Based on the two first-mentioned sources, environmental information is missing for many medicinal products. The database is based on Region Stockholm's work in Sweden and may mean, for example, that information about the Wise list, the formulary of recommended essential medicines for the entire Stockholm healthcare region, has been included.
The knowledge support Pharmaceuticals and Environment applies its own environmental criteria, which differ from the formal ERA system used by EMA/CHMP, and therefore cannot be directly applied in regulatory authorisation processes.
Information about the classification
In a document there is information about the classification of the environmental hazard and the environmental risk. The classification of the risk is usually based on theoretical calculations of the risk. For more information see Classification.
For some substances there is also a risk assessment made on the basis of concentrations measured in the environment in Sweden and efficacy studies with high quality. These assessments are presented in the documents for the substances and are made by independent ecotoxicological expertise. Continuous work is underway to provide more substance documents with this type of environmental information and also present comparisons of environmental risk between substances intended for the same indication. Based on this type of risk assessment, a table of environmentally hazardous drugs Pdf, 41 kB. was developed within the framework of Region Stockholm's environmental program 2017–2021.
News
2025
Jane J. Pappas, Natasha DesRochers, Bindu Tuteja, et al. Ecotoxicological implications of increased antidepressant concentrations in the Laurentian Great Lakes Basin, 2018–2023, Science of The Total Environment, Volume 981, 2025, 179331, ISSN 0048-9697, https://doi.org/10.1016/j.scitotenv.2025.179331.
Villén J, Laux J, Wettermark B, Sporrong SK, Nekoro M, Håkonsen H. Towards greener prescribing? Swedish general practitioners' support for policies to reduce pharmaceutical pollution. Br J Clin Pharmacol. 2025 Apr 27. doi: 10.1002/bcp.70066. Epub ahead of print. PMID: 40289270.
Brand JA, Michelangeli M, Shry SJ, et al. Pharmaceutical pollution influences river-to-sea migration in Atlantic salmon (Salmo salar). Science, 10 Apr 2025, Vol 388, Issue 6743, pp. 217–222, DOI: 10.1126/science.adp7174.
Martin JM, Michelangeli M, Bertram MG, et al. Evidence of the impacts of pharmaceuticals on aquatic animal behaviour (EIPAAB): a systematic map and open access database. Environmental Evidence (2025) 14:4 https://doi.org/10.1186/s13750-025-00357-6.
Fork ML, Fick J, Reisinger AJ, et al. Environmental conditions explain variabilityin concentrations of nutrients butnot emerging contaminants. Ecosphere. 2025;16:e70225. DOI: 10.1002/ecs2.70225.
Ella D. van Vliet, Nynke M. Kannegieter, Caroline T.A. Moermond, Teresa Leonardo Alves, Keystones in the implementation of greener pharmaceuticals: A scoping review, Sustainable Chemistry and Pharmacy, Volume 44, 2025, 101938, ISSN 2352-5541, https://doi.org/10.1016/j.scp.2025.101938.
Niemi L, Anderson C, Arakawa N, et al. Do you think medicines can be prescribed in a more eco-directed, greener way? A qualitative study based on public and prescriber focus groups on the impact of pharmaceuticals in Scotland’s water environment. BMJ Open 2025;15:e088066. doi:10.1136/bmjopen-2024-088066
A-Z list